Search

Yonsei University researchers have released new data on xenografts, specifically focusing on the use of anti-PTK7 monoclonal antibodies to suppress oncogenic phenotypes in cellular and xenograft models of triple-negative breast cancer (TNBC). The study highlights the potential of PTK7 as a therapeutic target in TNBC and demonstrates the anti-cancer effects of PTK7-neutralizing monoclonal antibodies both in vitro and in vivo. Further research on PTK7-targeted therapies, such as humanized monoclonal antibodies and antibody-drug conjugates, is recommended to advance treatment strategies for PTK7-positive TNBC. [Extracted from the article]

The article discusses a clinical trial, NCT06803355, focusing on differentiating between transient tachypnea of the newborn (TTN) and congenital pneumonia in neonates. The study aims to evaluate the clinical utility of inflammatory markers like the Systemic Immune-Inflammation Index (SII) and the Systemic Immune-Response Index (SIRI) in this differentiation. By utilizing these markers, clinicians hope to optimize antibiotic use and reduce hospitalization duration in neonates with respiratory distress. The trial is currently recruiting participants in Turkey and is set to be completed by June 1, 2025. [Extracted from the article]

The article discusses a clinical trial, NCT06794073, evaluating the efficacy of TACE combined with multimodal ablation, toripalimab, and lenvatinib in treating unresectable primary liver cancer. The study aims to assess the clinical value of multimodal ablation combined with systemic therapy and TACE by comparing preoperative and postoperative immune markers. The trial is still in the recruitment phase, with specific eligibility criteria for participants outlined in the study. [Extracted from the article]

A clinical trial, NCT06787612, is investigating the experimental drug ubamatamab for patients with advanced ovarian cancer. The study aims to assess the safety, tolerability, and effectiveness of ubamatamab alone and in combination with other anti-cancer drugs. The trial will also evaluate potential side effects, drug concentrations in the blood, and the development of antibodies against the study drug and its combinations. The study is set to enroll 220 participants with platinum-resistant ovarian cancer, with a primary completion date of April 30, 2028. [Extracted from the article]

The patent application titled "Composition Comprising Her2 Antibody, Formulation And Process Of Preparation Thereof" by Enzene Biosciences Limited focuses on developing pharmaceutical compositions containing HER2 antibodies, such as trastuzumab and pertuzumab, for the treatment of cancer. The invention aims to address the stability issues associated with existing formulations by incorporating specific buffers, stabilizers, and surfactants. The patent application outlines detailed compositions, formulations, and processes for preparing these HER2 antibody formulations, emphasizing the need for improved stability and ease of manufacturing. [Extracted from the article]

Researchers from Hasanuddin University conducted a study on the use of C-reactive protein (CRP) as a diagnostic marker for ovarian carcinoma. The study included 87 patients with ovarian carcinoma and ovarian cysts, aiming to improve early detection and clinical management of ovarian carcinoma. However, the research concluded that CRP levels did not significantly differ between ovarian carcinoma and ovarian cyst patients, indicating that CRP may not be an effective predictor to differentiate between the two conditions. The study highlighted age over 50 and menopausal status as significant risk factors for ovarian carcinoma. [Extracted from the article]

A recent study conducted at Baghdad Teaching Hospital examined the use of serum ferritin, C-reactive protein, and procalcitonin levels in predicting subclinical intra-amniotic infection in preterm premature rupture of membranes. The research found that procalcitonin may be a useful indicator for detecting chorioamnionitis, while serum ferritin and C-reactive protein levels did not play a significant role in its detection. This study provides valuable insights into potential early indicators for predicting intra-amniotic infections in pregnant women with preterm premature rupture of membranes. [Extracted from the article]

A clinical trial, NCT06767007, is being conducted to investigate the combination of stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer (ULRRC). The study aims to determine the safety and efficacy of this innovative combination therapy for ULRRC management. Participants will undergo a treatment regimen involving chemotherapy, SBRT, and PD-1 therapy, followed by surgery or maintenance therapy. The trial is set to enroll 31 participants and is expected to be completed by November 30, 2026. [Extracted from the article]

A patent application titled "Trans-Cyclooctene-Modified Bispecific Antibodies" was published online on January 9, 2025, by inventors from various locations in California. The application describes bispecific antibodies with trans-cyclooctene modifications that can target specific antigens on cancerous cells. These antibodies can be used in treating cancer, including metastatic cancers like melanoma, renal cancer, and pancreatic adenocarcinoma, among others. The patent application details the structure and potential therapeutic applications of these modified antibodies. [Extracted from the article]

The article discusses the potential of combining checkpoint inhibitors (CPI) with bispecific antibody armed T cell (BATs) therapy to enhance tumor clearance in hormone receptor-positive (HR+) breast cancers. The study identifies LAG3, PD-1, and TIGIT as inhibitory receptors expressed by cytotoxic effector CD8 BATs when exposed to HR+ breast cancer cells. A kinetic-dynamic mathematical model was developed to predict the contributions of T cells expressing each receptor to tumor reduction, with LAG3+ BATs identified as primary effectors. The findings aim to optimize CPI selection for BATs combination therapy and maximize anti-tumor function against HR+ cancers. [Extracted from the article]

A patent has been issued for cross-species single-domain antibodies targeting mesothelin to treat solid tumors. The antibodies, A101 and G8, bind both human and mouse mesothelin with high affinity and have shown potent anti-tumor activity in vitro and in vivo. The patent also covers methods of treating mesothelin-positive cancers, as well as compositions and constructs related to the antibodies. This patent provides valuable insights into potential therapeutic approaches for various solid tumors. [Extracted from the article]

Researchers from the Chinese Academy of Sciences have developed a new method for monitoring the expression of PD-L1 in tumors using 125I-labeled monoclonal antibodies. The study found that the labeled antibodies showed high specificity for PD-L1 imaging and maintained stability in vitro. This research has the potential to further explore the use of SPECT imaging with 125I-labeled antibodies to monitor PD-L1 expression in tumors. [Extracted from the article]

A recent study conducted at the Post Graduate Institute of Dental Sciences in Haryana, India, focused on the impact of ethinyl estradiol/norethisterone acetate (EE/NETA) on gingival and systemic inflammation in women with polycystic ovary syndrome (PCOS) and gingivitis. The randomized trial found that EE/NETA, with or without scaling, did not have a detrimental effect on gingiva and could reduce systemic and gingival inflammation in women with PCOS. The study concluded that periodontal parameters and serum high-sensitivity C-reactive protein (hsCRP) levels significantly decreased in all groups after 6 months of treatment. [Extracted from the article]

A recent study conducted by researchers at Inner Mongolia Medical University focused on monoclonal antibody therapy for triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer that lacks estrogen, progesterone, and HER2 receptors, making treatment challenging with a poor prognosis. The study highlights the potential of monoclonal antibody therapy in TNBC treatment, emphasizing the need for further research to optimize treatment regimens and improve patient outcomes. The research aims to serve as a reference for future studies on TNBC side effects, with a focus on enhancing patient prognosis and therapeutic results. [Extracted from the article]

A patent has been issued for antibodies targeting mucin-16 (MUC16) to treat MUC16-positive cancers, particularly ovarian cancer. The patent focuses on developing antibody constructs that bind to MUC16 and modulate its expression for therapeutic purposes. The inventors aim to provide new tools for diagnosing and treating MUC16-mediated disorders, such as cancer, by targeting specific regions of the MUC16 protein. [Extracted from the article]

A recent study conducted at Nagoya City University examined the association between antinuclear antibodies (ANA) and pregnancy outcomes in women with unexplained recurrent pregnancy loss (RPL). The study included 1021 women and found that ANA testing did not significantly impact the subsequent live birth rate in these patients. The results suggest that ANA testing may not be useful in predicting future pregnancy loss in women with RPL without a known cause. [Extracted from the article]

A recent study conducted at the First Hospital of China Medical University explored the potential link between anti-protein disulfide isomerase A3 autoantibody expression and the risk of polycystic ovary syndrome (PCOS) in euthyroid autoimmune thyroiditis (AIT) women. The research found that serum PDIA3Ab levels may indicate an increased risk of PCOS in these women and could potentially serve as new markers or targets for immune intervention. The study, published in the Journal of Ovarian Research, highlights the importance of understanding the underlying mechanisms of PCOS in women with AIT. [Extracted from the article]

A recent study conducted at Chirayu Medical College and Hospital in Madhya Pradesh, India, focused on the role of serum adenosine deaminase (ADA) and C-reactive protein (CRP) levels in preeclampsia, a common complication during pregnancy. The study compared 60 preeclampsia patients with 60 healthy pregnant women and found significantly higher levels of ADA and CRP in the preeclampsia group. The researchers suggest that these biomarkers could have diagnostic and prognostic value in preeclampsia, indicating potential immune system changes and inflammatory responses in the condition. [Extracted from the article]

Researchers at Regeneron Pharmaceuticals Inc. are investigating the use of ubamatamab, a bispecific antibody, for the treatment of ovarian cancer. The study involves intravenous administration of ubamatamab, either alone or in combination with an anti-programmed cell death-1 inhibitor, in patients with recurrent ovarian cancer. Preclinical and clinical data were integrated to determine dosing regimens, with a starting dose of 0.1 mg showing acceptable safety in patients. The research supports the evaluation of ubamatamab at specific concentrations for potential efficacy in treating ovarian cancer. [Extracted from the article]

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin, and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer is a clinical trial aiming to determine the efficacy and safety of zolbetuximab-based treatment in patients with LAGC. The trial focuses on Claudin 18.2 as a therapeutic target overexpressed in gastric cancer cells, with promising results from previous studies. The study design includes neoadjuvant chemotherapy followed by surgery and adjuvant treatment, with primary objectives of determining the recommended phase 2 dose and pathologic complete regression rate. [Extracted from the article]

A recent study from Ural State Medical University focused on the prognostic value of high-sensitivity C-reactive protein (hsCRP) levels in the first trimester for the risk of gestational diabetes mellitus (GDM) in obese pregnant women. The study included 105 obese women, with findings indicating a statistically significant increase in hsCRP concentration in women with GDM compared to those without. The research suggests that an hsCRP concentration above 0.5 mg/l could be a valuable screening tool for identifying early risk of GDM in obese pregnant women. [Extracted from the article]

A recent report from Regeneron Pharmaceuticals Inc. in Tarrytown, New York, discusses the investigation of ubamatamab, a bispecific antibody, for the treatment of ovarian cancer. The study focuses on regimen selection for a first-in-human trial, evaluating the safety and efficacy of ubamatamab in patients with recurrent ovarian cancer. Preclinical data supported the selection of starting doses and expansion regimens, integrating both animal and patient data to inform the study design. For more information, readers can refer to the original article in Clinical and Translational Science. [Extracted from the article]

Researchers at VCU Massey Comprehensive Cancer Center have identified a genetic code that enables cancer cells to recruit and deploy a gang of tumor cells, leading to a biological turf war within the body. Published in Nature Biotechnology, this discovery could revolutionize our understanding of cancer origins and treatment strategies. The study authors have developed a monoclonal antibody therapy that empowers healthy cells to resist invading tumor cells, showing promise in ovarian cancer and potentially applicable to all cancer types. This groundbreaking research highlights the importance of early detection and offers hope for new treatments targeting tumors in their earliest stages. [Extracted from the article]

A recent study conducted at Renmin Hospital of Wuhan University in China explored the relationship between C-reactive protein (CRP) levels and the efficacy of neoadjuvant chemotherapy for hormone receptor-positive breast cancer. The research found that high CRP levels were associated with a higher pathological complete response rate in hormone receptor-positive patients, indicating a potential predictive value for treatment outcomes. The study concluded that CRP levels could serve as an independent predictor of treatment efficacy in this specific patient population. [Extracted from the article]

A patent has been issued for immunoconjugates targeting CD46 for the treatment of cancers such as breast, colorectal, liver, lung, and prostate cancer. The patent, assigned to Fortis Therapeutics Inc., focuses on providing therapies for conditions characterized by cell surface CD46 expression, like metastatic castration resistant prostate cancer and multiple myeloma. The patent outlines methods of administering immunoconjugates to human subjects at specific doses and intervals, targeting CD46 with an antibody conjugated to monomethylauristatin E (MMAE) for treatment. [Extracted from the article]

A patent application for a new protein that binds to PD-1, a receptor involved in cancer treatment, has been filed by inventors from Shanghai, China. The protein, along with related antibodies, is designed to enhance T cell and NK cell activation, potentially improving cancer immunotherapy outcomes. This innovative approach targets multiple immune checkpoints simultaneously, offering a promising avenue for future cancer treatments. [Extracted from the article]

A study conducted at the University of British Columbia in Vancouver, Canada, focused on neutralizing antibody responses to Chlamydia trachomatis in women and their associations with chlamydia outcomes. The research found varying rates of neutralization in women with different infection outcomes, with higher neutralization rates in women with spontaneous resolution compared to those with persisting infection before treatment. The study suggests that neutralizing antibody responses may play a role in protective immunity against chlamydia. [Extracted from the article]

The article from Women's Health Weekly discusses research conducted by the Department of Obstetrics and Gynecology on spontaneous abortion, specifically focusing on threatened miscarriage. The study evaluated the correlation between serum C-reactive protein (CRP) levels and fetal ultrasound parameters in predicting threatened miscarriage during the first trimester of pregnancy. Findings indicated that patients with threatened miscarriage had significantly elevated CRP levels, suggesting a potential utility of CRP levels in conjunction with ultrasound parameters for prognosticating threatened miscarriage. The research was published in the Qatar Medical Journal and can be accessed for further information. [Extracted from the article]

A recent study from the Cancer Biology Laboratory in Andhra Pradesh, India, explores the immune landscape of breast cancer, focusing on the role of immunoglobulin-binding protein (BiP) and Toll-like receptors (TLRs) in personalized medicine. The research highlights the significance of BiP in regulating the unfolded response pathway of proteins and its impact on TNBC metastasis, drug resistance, and the tumor microenvironment. The study suggests that understanding the interplay between BiP, TLRs, and the immune response could lead to novel immunotherapies and targeted therapies for personalized medicine in triple-negative breast cancer. [Extracted from the article]

A novel CAR T-cell therapy has been developed by researchers at the Vall d'Hebron Institute of Oncology to target HER2-positive solid tumors expressing the P95HER2 protein, associated with aggressive breast cancer. This therapy, utilizing T cells engineered with a CAR against p95HER2 and a bispecific antibody, has shown safety and complete antitumor responses in preclinical models. A phase 1 clinical trial is being planned to evaluate this therapy in patients with HER2-overexpressing tumors, supported by the Asociacion Espanola Contra el Cancer and the Instituto de Salud Carlos III. This research represents a promising strategy to improve outcomes for patients with HER2-positive tumors. [Extracted from the article]

A recent study conducted at Kepler University Hospital in Linz, Austria, focused on the use of C-reactive protein (CRP) as a tool to rule out infection after cesarean section. The study included 2056 patients over a 3-year period, with 78 cases (3.8%) experiencing postoperative infection. While CRP values were higher in the infection group, the study did not find a reliable cut-off value for ruling out infection, suggesting that CRP testing may not be a dependable tool for diagnosing or ruling out postoperative infection. For more information, readers can refer to the journal article "Retrospective Evaluation of C-reactive Protein for Ruling Out Infection After Cesarean Section" in Geburtshilfe und Frauenheilkunde. [Extracted from the article]

A clinical trial, NCT06670963, aims to address anemia in ICU patients with sepsis or septic shock by evaluating the effects of epoetin alfa and iron derisomaltose on hemoglobin levels and blood transfusion rates. The study targets the root causes of anemia in these patients, focusing on increasing hemoglobin levels and reducing transfusions to improve treatment outcomes. The trial involves 200 patients and includes specific inclusion and exclusion criteria, treatment protocols, and laboratory parameters to monitor. The primary and secondary endpoints of the study focus on hemoglobin differences, transfusion rates, mortality, and prevalence of complications like deep vein thrombosis and pulmonary embolism. [Extracted from the article]

Researchers at Mustansiriyah University in Baghdad, Iraq, conducted a study to assess the role of inflammatory markers, specifically serum ferritin and C-reactive protein, as indicators of preeclampsia severity in pregnant women. The study included 87 pregnant women divided into severe preeclampsia, non-severe preeclampsia, and control groups. The research found that C-reactive protein levels were significantly associated with the severity of preeclampsia, showing a discriminative ability between severe and non-severe cases. This study provides valuable insights into potential indicators of preeclampsia severity in pregnant women. [Extracted from the article]

A recent study from Seoul National University Children's Hospital highlights the challenges in diagnosing lupus nephritis (LN) due to overlapping symptoms with other conditions like immunoglobulin A nephropathy (IgAN). The case report discusses a pediatric patient initially misdiagnosed with IgAN, later found to have LN with lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS). The study emphasizes the importance of clinical suspicion, integrating various data, and considering LAHPS in the differential diagnosis of glomerulonephritis with coagulopathy. [Extracted from the article]

A patent has been issued for an anti-BAG2 antibody by Medpacto Inc., which specifically binds to a BAG2 polypeptide involved in cancer treatment. The antibody targets the BAG2 protein, which plays a role in apoptosis, cell proliferation, and neurodegenerative diseases. This patent aims to develop an antibody that can inhibit cancer progression by targeting BAG2, potentially improving treatment outcomes for cancer patients. [Extracted from the article]

A patent application by inventors Casciola-Rosen, Ewald, Padmanaban, and Rosen explores the use of autoimmune antibodies to inhibit cancer cell growth, particularly in breast cancer. The application highlights the potential of autoimmune antibodies from patients with autoimmune diseases to target gene products associated with cancer progression. The methods described in the patent application offer diagnostic, screening, and therapeutic applications for various types of cancer, including lung, breast, colon, and pancreatic cancer, among others. The research aims to address the urgent need for improved treatments for metastatic breast cancer, emphasizing the role of autoimmune antibodies in controlling tumor progression. [Extracted from the article]

A recent study conducted at Zhejiang Chinese Medical University explored the association between serum vitamin D levels, uric acid, C-reactive protein, and disease severity in ulcerative colitis (UC) patients. The research found that low serum vitamin D levels may be linked to more severe UC, with males showing higher levels of uric acid and C-reactive protein compared to females. The study highlights the importance of gender in understanding disease severity and the potential impact of vitamin D levels on UC patients. [Extracted from the article]

The article discusses the role of autoantibodies in predicting spontaneous preterm delivery, which is a leading cause of global mortality in children under age five. Through proteome-wide autoantibody profiling, researchers identified autoreactivities associated with imminent preterm delivery in maternal sera across four cohorts of human pregnancy. The study found that spontaneous preterm pregnancies exhibit greater proteome-wide autoreactivity, with enrichment for pathways critical for normal pregnancy outcomes, including vascular development, reproductive hormones, and regulators of inflammation. The findings suggest potential utility for serologic diagnostics in stratifying the risk of spontaneous preterm delivery and managing IL1? during pregnancy. [Extracted from the article]

The patent application titled "Methods And Compositions For Treating Cancer" discusses the development of a bispecific antibody targeting PD-1 and LAG3 for the treatment of various cancers, including melanoma and liver cancer. The method involves administering the bispecific antibody at a fixed dose of 600 mg every three weeks. The application highlights the urgent need for novel therapeutic approaches in cancer treatment due to the increasing incidence and significant global public health impact of cancers like melanoma and liver cancer. [Extracted from the article]

The USPTO has published a patent application titled "Antibodies Against Pd-L1" by inventors ALTINTAS, Isil; DE GOEIJ, Bart; PARREN, Paul; RADEMAKER, Rik; SATIJN, David; VAN DEN BRINK, Edward; and VERZIJL, Dennis. The application discusses the development of novel anti-PD-L1 antibodies that can bind to human PD-L1 and inhibit its interaction with human PD-1. These antibodies have potential applications in cancer treatment. The application provides detailed information on the amino acid sequences of the antibodies and their variable regions, as well as the possibility of creating bispecific antibodies that can bind to both PD-L1 and another antigen. [Extracted from the article]

A patent has been issued to OBI Pharma Inc. for conjugated biological molecules, pharmaceutical compositions, and methods. The patent focuses on the use of antibody-drug conjugates (ADCs) for targeted cancer therapy. Specifically, the patent highlights the potential of Globo series antigens as unique targets for cancer therapies and the development of ADCs to effectively target cancer cells. The patent also mentions specific antibodies, such as OBI-888, and therapeutic agents, such as monomethyl auristatin E (MMAE), that can be used in the ADCs. The patent claims methods of treating cancer by administering ADCs to subjects with Globo H-expressing cancers, including breast cancer, pancreatic cancer, gastric cancer, and lung cancer. [Extracted from the article]

A recent study conducted at the IRCCS Humanitas Research Hospital in Italy explored the association between systemic sclerosis (SSc) and an increased risk of cancer, particularly breast cancer. The study found that SSc patients had a higher prevalence of cancer, with 8% of cases being cancer-associated scleroderma. Elderly patients and those with positive anti-Ro52 or anti-U3-RNP antibodies were more likely to develop cancer. The study also found that patients who were negative for certain SSc-related autoantibodies had a higher risk of breast cancer. The researchers concluded that cancer surveillance should be particularly careful in patients with diffuse SSc, increased age at disease onset, and without classical SSc-related autoantibodies. [Extracted from the article]

A recent study conducted at the University of Health Sciences in Ankara, Turkey, aimed to evaluate the effectiveness of changes in C-reactive protein (CRP), procalcitonin, and leukocyte counts in predicting the prognosis of patients with sepsis and pneumonia-related septic shock. The study analyzed data from 230 patients admitted to the intensive care unit (ICU) between April 2022 and December 2023. The results showed that persistent elevation and concurrent increase in CRP, procalcitonin, and leukocyte values, along with male gender, advanced age, low BMI, and high comorbidity scores, were significantly associated with 3-month mortality in patients with pneumoseptic or pneumonia-related septic shock. [Extracted from the article]

A patent application titled "Anti-Slc34a2 Monoclonal Antibodies And Uses Thereof" has been published online. The application discusses the discovery of antibodies that have high binding affinity to the human SLC34A2 protein and are effective in mediating antibody-dependent cellular cytotoxicity (ADCC) and inducing cytotoxicity. These antibodies show potential for treating diseases such as cancer. The patent application provides detailed information about the antibodies, their amino acid sequences, and their potential uses in treating various types of cancer. [Extracted from the article]

A patent has been issued for an anti-Her2 nanobody and its coding sequence. Her2 is a protein that plays a role in various types of cancer, including breast cancer. The patent describes the development of specific nanobodies that target Her2, which are smaller and more stable than conventional antibodies. These nanobodies have potential applications in targeted therapies and imaging techniques for Her2-positive tumors. The patent provides amino acid sequences and claims for the nanobodies, as well as their use in pharmaceutical compositions and methods of treating Her2-positive tumors. [Extracted from the article]

A patent application titled "Methods And Materials For Treating Cancer" has been published online. The inventors propose materials and methods for assessing and treating mammals, including humans with autoimmune diseases. The document describes the use of specific antibodies to determine the risk of cancer in individuals with dermatomyositis (DM), an autoimmune disease. The presence or absence of certain autoantibodies can indicate a higher or lower risk of cancer, and these findings can be used to guide treatment decisions. The patent application also discusses methods for selecting patients for increased monitoring and administering inhibitors to treat cancer. [Extracted from the article]

A study published in Women's Health Weekly suggests that patients with metastatic breast cancer have an increased risk of sudden cardiac death (SCD) due to autoantibodies targeting the cardiac NaV1.5 sodium channel. These autoantibodies can trigger arrhythmias and reduce sodium current density, potentially leading to fatal arrhythmias. The study highlights the need for reliable diagnostic tests and targeted therapies to mitigate SCD risk in affected patients. However, it should be noted that this study is a preprint and has not been peer-reviewed. [Extracted from the article]

A patent application titled "Methods Of Treating Cancer With Bispecific Egfr Xcd28 Antibodies Alone Or In Combination With Anti-Pd-1 Antibodies" is currently being reviewed. The application outlines a method for treating cancer by using a combination of two antibodies. One antibody targets CD28 and EGFR, while the other specifically binds to PD-1. The method includes specific dosing instructions for the administration of the antibodies. It is intended for the treatment of various types of cancer, such as cervical, colorectal, lung, and breast cancer. For more information and specific claims, refer to the full patent application. [Extracted from the article]